21 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Chang, Radiation Oncologist in Ann Arbor, MI?
Where did Dr. Chang go to medical school and complete their residency?
Residency: University of Florida
Is Dr. Chang board certified as a Radiation Oncologist?
Yes, Dr. Daniel Chang, MD is board certified by the American Board of Radiology since 2008
What languages does Dr. Chang speak?
Dr. Chang and their clinical team can communicate with patients in the following languages:
- English
What conditions does a Radiation Oncologist like Dr. Chang typically treat?
As a Radiation Oncologist, Dr. Chang diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Chang. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Liver Cancer
- Cancer Spread to Liver and Bile Duct
- Childhood Liver Cancer
- Hepatic Cancer
- Hepatocellular Carcinoma
- Metastatic Liver Cancer
- Secondary Liver Tumor
- Liver Metastasis
ICD-10 Codes:
- C220: Liver cell carcinoma
- C787: Secondary malignant neoplasm of liver and intrahepatic bile duct
Also known as:
- Secondary Bone Cancer
- Secondary Brain Cancer
- Bone Cancer
- Brain Tumor
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
- Metastatic brain cancer
- Brain metastases
- Cancer spread to brain
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
- C7931: Secondary malignant neoplasm of brain
Also known as:
- Colorectal Cancer
- Rectal cancer
- Colon cancer
- Bowel cancer
- Malignant neoplasm of rectum
ICD-10 Codes:
- C20: Malignant neoplasm of rectum
Also known as:
- Bile Duct Cancer
- Liver Cancer
- Cholangiocarcinoma
- Intrahepatic cholangiocarcinoma
ICD-10 Codes:
- C221: Intrahepatic bile duct carcinoma
What procedures does a Radiation Oncologist like Dr. Chang typically perform?
As a Radiation Oncologist, procedures performed by Dr. Daniel Chang may include:
- Abdominal Aortic Aneurysm (AAA) Screening
- Abdominal Imaging
- Abdominal Radiology Consultation
- Angiography
- Arthrography
- Barium Swallow
- Bone Biopsy
- Bone Density Measurement / DXA Scan
Please contact Dr. Chang's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Chang accept my insurance?
Dr. Chang accepts most major insurance plans. Important: Please call our office at (650) 736-7143 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Chang accept in Ann Arbor, MI?
Dr. Chang in Ann Arbor, MI accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
Blue Cross Blue Shield of Michigan
Centene Corporation
CVS Health (formerly Aetna)
Henry Ford Health System
Humana
McLaren Health Care
Medicare
Molina Healthcare
Spectrum / Priority Health
UnitedHealth Group
View All Insurances
Where is Dr. Chang's office located?
Dr. Daniel Chang's Primary Practice
1500 E Medical Center Dr
Ann Arbor, MI 48109
(650) 736-7143
What hospitals are Dr. Chang affiliated with?
Castle Connolly Top Hospital
This doctor is affiliated with a Castle Connolly Top Hospital.
Dr. Chang has admitting privileges at the following hospitals:
Recognitions
Publications
Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer, 2014
Combined-modality Therapy for Rectal Cancer Alysis of Potential Differences in Disease Presentation, 2014
Impact of chemotherapy on normal tissue complication probability models of acute hematologic, 2013
Safety of (90)y radioembolization in patients who have undergone previous exterl beam radiation, 2013
Radiotherapy for nodenoid cystic carcinomas of major salivary glands., 2013
Seventh Edition (2010) of the AJCC, 2013
A Phase 2 Multi-institutiol Study to Evaluate Gemcitabine, 2013
Dosimetric alysis of organs at risk during expiratory gating, 2013
Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer
Metabolic Tumor Volume Predicts Disease Progression, 2013
Signet Ring Cell Colorectal Carcinoma
Clinicopathologic Features of Synchronous Colorectal Carcinoma
Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images, 2012
Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes, 2012
Combined Modality Therapy for Rectal Cancer, 2012
A phase II multi-institutiol study to evaluate gemcitabine
Intensity-Modulated Radiotherapy for Tumors of the sal Cavity and Parasal Sinuses, 2012
BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon, 2012
Combined-modality Therapy for Rectal Cancer
SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF, 2011
Stereotactic Body Radiotherapy for Colorectal Liver Metastases A Pooled Alysis, 2011
Intensity-Modulated Radiation Therapy Versus Conventiol Radiation Therapy for Squamous Cell, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR ORAL CAVITY SQUAMOUS CELL CARCINOMA, 2011
PROSPECTIVE RANDOMIZED DOUBLE-BLIND PILOT STUDY OF SITE, 2011
Pattern of Lymph Node Involvement and Prognosis in Pancreatic Adenocarcinoma, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX, 2011
Gastrointestil Normal Tissue Toxicity Prediction In Stereotactic Body Radiotherapy, 2011
Stereotactic Body Radiation Therapy for Gastrointestil Maligncies, 2011
A DOSIMETRIC MODEL OF DUODEL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR PANCREATIC CANCER, 2010
Comparison of Intensity-Modulated Radiotherapy, 2010
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION, 2010
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER, 2010
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer, 2010
INTERFRACTIOL UNCERTAINTY IN THE TREATMENT OF PANCREATIC CANCER WITH RADIATION, 2010
Stereotactic Body Radiotherapy for Colorectal Liver Metastases: A Pooled Alysis, 2010
Combined Modality Therapy for Rectal Cancer, 2010
Significant Duodel Dose Variation within the Respiratory Cycle during Stereotactic Body, 2010
Comparison of RapidArc vs. Conventiol Intensity Modulated Radiation Therapy, 2010
Intensity Modulated Radiation Therapy vs. Conventiol Radiation Therapy, 2010
Identification of a biomarker panel using a multiplex proximity ligation, 2009
Pancreatic Tumor Motion on a Single Planning 4D, 2009
Treatment of Esophageal Cancer Based on Histology A Surveillance Epidemiology, 2009
Long-term Outcomes for Stage I-II Aggressive Non-Hodgkin Lymphoma of Waldeyer's Ring, 2009
Percutaneous Implantation of Fiducial Markers for Imaging-Guided Radiation Therapy, 2009
Xerostomia in Long-term Survivors of Aggressive Non, 2009
Safety and Efficacy of Percutaneous Fiducial Marker Implantation for Image-guided Radiation Therapy, 2009
Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible?, 2007
Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with, 2007
Predicting changes in dose distribution to tumor, 2007
Adjuvant radiotherapy for cutaneous melanoma: Comparing hypofractiotion to conventiol fractiotion, 2006
The impact of heterogeneity correction on dosimetric parameters that predict, 2006
Re-examining the role of elective nodal irradiation, 2005
Merkel cell carcinoma of the skin with leptomeningeal metastases, 2005
Dose-dependent effects of D-damaging agents on p53-mediated cell cycle arrest, 1999
Stereotactic Body Radiotherapy in the Treatment of Pancreatic Cancer, 2014
Combined-modality Therapy for Rectal Cancer Analysis of Potential Differences in Disease, 2014
Impact of chemotherapy on normal tissue complication probability models of acute hematologic, 2013
Long-Term Outcomes of Surgery Followed by Radiation Therapy for Minor Salivary Gland Carcinomas, 2013
Safety of (90)y radioembolization in patients who have undergone previous external beam radiation, 2013
Radiotherapy for nonadenoid cystic carcinomas of major salivary glands., 2013
Seventh Edition (2010) of the AJCC, 2013
A Phase 2 Multi-institutional Study to Evaluate Gemcitabine, 2013
Dosimetric analysis of organs at risk during expiratory gating, 2013
Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer
Metabolic Tumor Volume Predicts Disease Progression, 2013
Signet Ring Cell Colorectal Carcinoma
Clinicopathologic Features of Synchronous Colorectal Carcinoma
Future directions in combined modality therapy for rectal cancer, 2013
SBRT as a Novel Treatment Option for Locally Recurrent Pancreatic Cancer After Failure of, 2012
Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity, 2012
Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity, 2012
Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response, 2012
Esophageal tolerance to high-dose stereotactic ablative radiotherapy, 2012
Positron Emission Tomography for Predicting Pathologic Response, 2012
Intrafraction Verification of Gated RapidArc by Using Beam-Level Kilovoltage X-Ray Images, 2012
Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes, 2012
Combined Modality Therapy for Rectal Cancer, 2012
Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma, 2012
Orthovoltage Intraoperative Radiotherapy for Locally Advanced and Recurrent Colorectal Cancer, 2012
A phase II multi-institutional study to evaluate gemcitabine
Intensity-Modulated Radiotherapy for Tumors of the Nasal Cavity and Paranasal Sinuses, 2012
BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon, 2012
Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma, 2012
Modern Radiation Therapy Techniques for Pancreatic Cancer, 2012
Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer, 2012
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population, 2012
Combined-modality Therapy for Rectal Cancer
A rare case of an aldosterone secreting metastatic adrenocortical carcinoma, 2011
SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF, 2011
Stereotactic Body Radiotherapy for Colorectal Liver Metastases A Pooled Analysis, 2011
Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR ORAL CAVITY SQUAMOUS CELL CARCINOMA, 2011
Rectal and bladder deformation and displacement during preoperative radiotherapy for rectal cancer, 2011
PROSPECTIVE RANDOMIZED DOUBLE-BLIND PILOT STUDY OF SITE, 2011
Pattern of Lymph Node Involvement and Prognosis in Pancreatic Adenocarcinoma, 2011
INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX, 2011
Gastrointestinal Normal Tissue Toxicity Prediction In Stereotactic Body Radiotherapy, 2011
Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation, 2011
Radiotherapy For Adenoid Cystic Carcinomas Of The Head and Neck, 2011
Dosimetric Comparison of RapidArc versus CyberKnife for Stereotactic Body Radiation Therapy for, 2011
Stereotactic Body Radiation Therapy for Gastrointestinal Malignancies, 2011
A DOSIMETRIC MODEL OF DUODENAL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR PANCREATIC CANCER, 2010
Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate, 2010
Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma, 2010
Comparison of Intensity-Modulated Radiotherapy, 2010
(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION, 2010
Pathological response after chemoradiation for T3 rectal cancer., 2010
Pathological response after chemoradiation for T3 rectal cancer, 2010
INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER, 2010
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer, 2010
INTERFRACTIONAL UNCERTAINTY IN THE TREATMENT OF PANCREATIC CANCER WITH RADIATION, 2010
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer, 2010
Stereotactic Body Radiotherapy for Colorectal Liver Metastases: A Pooled Analysis, 2010
Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head and Neck Cancer Outcomes, 2010
Combined Modality Therapy for Rectal Cancer, 2010
Significant Duodenal Dose Variation within the Respiratory Cycle during Stereotactic Body, 2010
Comparison of RapidArc vs. Conventional Intensity Modulated Radiation Therapy, 2010
Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy, 2010
Identification of a biomarker panel using a multiplex proximity ligation, 2009
Pharmacologically Increased Tumor Hypoxia Can Be Measured by F-18, 2009
Pancreatic Tumor Motion on a Single Planning 4D, 2009
Treatment of Esophageal Cancer Based on Histology A Surveillance Epidemiology, 2009
Long-term Outcomes for Stage I-II Aggressive Non-Hodgkin Lymphoma of Waldeyer's Ring, 2009
Percutaneous Implantation of Fiducial Markers for Imaging-Guided Radiation Therapy, 2009
Xerostomia in Long-term Survivors of Aggressive Non, 2009
Safety and Efficacy of Percutaneous Fiducial Marker Implantation for Image-guided Radiation Therapy, 2009
Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas, 2009
A Prospective Randomized Pilot Study of Site, 2009
Stereotactic body radiotherapy for unresectable adenocarcinoma of the pancreas, 2008
Do pre-irradiation dental extractions reduce the risk of osteoradionecrosis of the mandible?, 2007
Long-term outcomes in breast cancer patients with ten or more positive axillary nodes treated with, 2007
Predicting changes in dose distribution to tumor, 2007
Adjuvant radiotherapy for cutaneous melanoma, 2006
The impact of heterogeneity correction on dosimetric parameters that predict, 2006
Re-examining the role of elective nodal irradiation, 2005
Merkel cell carcinoma of the skin with leptomeningeal metastases, 2005
Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors, 2000
Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest, 1999
What is Dr. Chang's NPI number?A National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Chang's National Provider Identifier (NPI) number is 1285722892.
What common questions do patients ask about Dr. Chang?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Chang